Top Markets
#1 Pleasing Gold Pleasing Gold +1,546.27%
#2 PulseChain PulseChain +61.61%
#3 Ontology Gas Ontology Gas +36.94%
#4 DogBull DogBull +36.89%
#5 BOOK OF MEME BOOK OF MEME +30.55%
#6 Neiro Neiro +21.85%
#7 Collect on Fanable Collect on Fanable +21.43%
#8 Nockchain Nockchain +19.56%
#9 Pump.fun Pump.fun +19.14%
#10 Unit Pump Unit Pump +19.14%
Coin of the day
Pleasing Gold Pleasing Gold
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
PharmAust Limited PharmAust Limited

PharmAust Limited

PAA
Rang in Aktien #26700
Operating internationally, including in Switzerland, Australia, Sweden, and the... Operating internationally, including in Switzerland, Australia, Sweden, and the United States, PharmAust Limited specializes in developing targeted cancer treatments for both human and animal applications. The company also cultivates intellectual property in drug discovery, addressing a range of cancers and neurological conditions. Its primary therapeutic candidate is Monepantel (MPL), a small molecule compound currently undergoing Phase II clinical trials for cancer treatment. Beyond its drug development pipeline, PharmAust provides synthetic and medicinal chemistry products and expert services to the global drug discovery and pharmaceutical sectors. The firm also holds a research agreement with the Walter and Eliza Hall Institute, investigating in vitro the effects of MPL on human T-lymphotrophic virus-1 (HTLV-1) infections. Established in 2000, PharmAust Limited is headquartered in Bentley, Australia.
Aktienkurs
$0.12164306
Zuletzt synchronisiert: 2024-11-11
Marktkapitalisierung
$38.53M
Veränderung (1 Tag)
-4.14%
Veränderung (1 Jahr)
0.00%
Land
AU
Handel PharmAust Limited (PAA)

Kategorie

Healthcare
P/S-Verhältnis für PharmAust Limited (PAA)
P/S-Verhältnis zum August 2026 TTM: 0.00
Laut den neuesten Finanzberichten und dem Aktienkurs von PharmAust Limited beträgt das aktuelle Kurs-Umsatz-Verhältnis (TTM) 0.00. Am Ende des Jahres 2024 lag das P/S-Verhältnis bei 0.00.
P/S-Verlauf für PharmAust Limited von 2001 bis 2026
P/S-Verhältnis zum Jahresende
Jahr P/S-Verhältnis ändert
2026 (TTM) 0.00 0.00%
2025 0.00 0.00%
2024 0.00 -100.00%
2023 8.53 29.96%
2022 6.56 -51.13%
2021 13.42 -6.50%
2020 14.36 611.37%
2019 2.02 20.63%
2018 1.67 -19.73%
2017 2.08 -15.55%
2016 2.47 -36.92%
2015 3.91 -40.73%
2014 6.60 108.20%
2013 3.17 87.09%
2012 1.70 -67.92%
2011 5.28 -58.41%
2010 12.70 360.27%
2009 2.76 66.79%
2008 1.65 66.92%
2007 0.99 -42.02%
2006 1.71 -41.66%
2005 2.93 -80.04%
2004 14.68 -38.19%
2003 23.75 159.55%
2002 9.15 0.00%
2001 0.00 0.00%
P/S-Verhältnis für ähnliche Unternehmen oder Wettbewerber
Unternehmen P/S-Verhältnis P/S-Verhältnis-Differenz Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
10.17 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
10.13 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
2.95 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
11.28 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH